Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Non-Current Deferred Tax Liability: 2022-2024

  • ProQR Therapeutics N.V's Non-Current Deferred Tax Liability fell 21.81% to $3.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.2 million, marking a year-over-year decrease of 21.81%. This contributed to the annual value of $3.2 million for FY2024, which is 22.23% down from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported Non-Current Deferred Tax Liability of $3.2 million as of Q4 2024, which was down 21.81% from $4.0 million recorded in Q4 2023.
  • Over the past 5 years, ProQR Therapeutics N.V's Non-Current Deferred Tax Liability peaked at $4.0 million during Q4 2023, and registered a low of $3.2 million during Q4 2024.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $3.8 million (2022), whereas its average is $3.7 million.
  • Per our database at Business Quant, ProQR Therapeutics N.V's Non-Current Deferred Tax Liability rose by 5.74% in 2023 and then fell by 21.81% in 2024.
  • Over the past 3 years, ProQR Therapeutics N.V's Non-Current Deferred Tax Liability (Quarterly) stood at $3.8 million in 2022, then increased by 5.74% to $4.0 million in 2023, then dropped by 21.81% to $3.2 million in 2024.
  • Its Non-Current Deferred Tax Liability was $3.2 million in Q4 2024, compared to $4.0 million in Q4 2023 and $3.8 million in Q4 2022.